<DOC>
	<DOCNO>NCT01325740</DOCNO>
	<brief_summary>The study consist Screening period ( 14 day ) , Treatment period , Follow-Up period . Sixteen subject enrol two sequential dose cohort - 10 30 mg ( match placebo ) across four study center .</brief_summary>
	<brief_title>A Study Assess Tolerability Single Dose STX107 Adults With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male subject 18 50 year age , inclusive . Molecular documentation full fragile X mutation . Subjects history seizure disorder , opinion Investigator Medical Monitor , currently consider well control . Subjects currently treat psychoactive medication ( include stimulant anxiolytic ) . Subjects condition , include alcohol drug abuse , might interfere conduct study , confound interpretation study result , endanger wellbeing . 4 . Subjects plan initiate change pharmacologic nonpharmacologic intervention course study . Subjects , Investigator 's opinion , might suitable study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>